CREXONT® (carbidopa and levodopa) Extended-Release Capsules

Crexont® (carbidopa and levodopa) extended-release capsules email format

Verified email-pattern data for Crexont® (Carbidopa And Levodopa) Extended-Release Capsules is currently limited. You can still use the company insights and contact sections below.
Welcome to the official LinkedIn page for CREXONT®, a novel formulation of extended-release carbidopa and levodopa. Please see Important Safety Information on LinkedIn page and the full Prescribing Information here: https://amneal.com/pi/crexont.pdf Indication CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults. IMPORTANT SAFETY INFORMATION Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors. Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider. CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you. The most common side effects that may occur with CREXONT are nausea and anxiety. Use in Specific Populations Pregnancy: Based on animal data, CREXONT may cause fetal harm. There are no adequate data on the developmental risk associated with the use of CREXONT in pregnant women. Breastfeeding: The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CREXONT. Geriatric patients: There were no differences in safety outcomes between patients less than 65 years of age, 65-75 years of age, or 75 years and older. To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1‑877‑835‑5472 or the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. PP-CREX-US-0011 1/2025
Looking for a particular CREXONT® (carbidopa and levodopa) Extended-Release Capsules employee's phone or email?

Crexont® (Carbidopa And Levodopa) Extended-Release Capsules Questions

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant